Annals of Oncology Advance Access originally published online on November 6, 2007
Annals of Oncology 2008 19(3):465-472; doi:10.1093/annonc/mdm509
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
breast cancer |
Expression of ER, PgR, HER1, HER2, and response: a study of preoperative chemotherapy
1 Unit of Research in Medical Senology, Division of Medical Oncology, Department of Medicine, European Institute of Oncology, Milan
2 Division of Pathology, European Institute of Oncology
3 School of Medicine, University of Milan, Milan, Italy
4 International Breast Cancer Study Group, Statistical Center, Dana-Farber Cancer Institute, and Frontier Science and Technology Research Foundation, Boston, MA, USA
5 Division of Senology, European Institute of Oncology, Milan
6 Department of Medicine, European Institute of Oncology, Milan, Italy
* Correspondence to: Dr M. Colleoni, Unit of Research in Medical Senology, Division of Medical Oncology, Department of Medicine, European Institute of Oncology, Via Ripamonti 435, 20141, Milan, Italy. Tel: +39-02-57489439; Fax: +39-02-57489212; E-mail: marco.colleoni{at}ieo.it
Purpose: To identify the role of estrogen (ER), progesterone (PgR), epidermal growth factor 1 (HER1), and HER2 receptors in predicting response to preoperative chemotherapy.
Materials and methods: We reviewed the pretreatment biopsies of 485 patients with locally advanced breast cancer (cT2-T4, N0-2, M0) treated with preoperative chemotherapy. The incidence of pathological complete remission (pCR) and outcome were assessed with respect to clinical and pathological findings including ER/PgR status (absent versus expressed), HER1 (absent versus expressed) and HER2 (overexpressed versus none) expression.
Results: Patients with ER/PgR-absent tumors were 12.0 times [95% confidence interval (CI) 4.93–29.28] more likely to achieve a pCR (P < 0.0001). Predictors of disease-free survival (DFS) at the univariate analysis included HER1 [hazards ratio (HR) 1.6, 95% CI 1.04–2.32, P = 0.03] and HER2 (HR 1.6, 95% CI 1.08–2.38, P = 0.02) expression. A statistically significant difference in DFS was confirmed at the multivariate analysis for patients with ER/PgR-absent disease (HR 2.1, 95% CI 1.41–2.99, P = 0.0002).
Conclusions: The pCR rate is higher and outcome worse for patients with ER/PgR-absent tumors. HER1 and HER2 expression may have a prognostic role in locally advanced breast cancer and warrant further studies.
Key words: breast cancer, predictive factors, prognostic factors, primary chemotherapy
Received for publication July 13, 2007. Revision received October 1, 2007. Accepted for publication October 2, 2007.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  P. Castorina, D. Carco, C. Guiot, and T. S. Deisboeck Tumor Growth Instability and Its Implications for Chemotherapy Cancer Res., November 1, 2009; 69(21): 8507 - 8515. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Jinno, M. Sakata, T. Hayashida, M. Takahashi, M. Mukai, T. Ikeda, and Y. Kitagawa A phase II trial of capecitabine and docetaxel followed by 5-fluorouracil/epirubicin/cyclophosphamide (FEC) as preoperative treatment in women with stage II/III breast cancer Ann. Onc., October 23, 2009; (2009) mdp428v1. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Goldhirsch, J. N. Ingle, R. D. Gelber, A. S. Coates, B. Thurlimann, H.-J. Senn, and Panel members Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2009 Ann. Onc., August 1, 2009; 20(8): 1319 - 1329. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. MIGLIETTA, P. VANELLA, L. CANOBBIO, M. A. PARODI, P. GUGLIELMINI, and F. BOCCARDO Clinical and Pathological Response to Primary Chemotherapy in Patients with Locally Advanced Breast Cancer Grouped According to Hormonal Receptors, Her2 Status, Grading and Ki-67 Proliferation Index Anticancer Res, May 1, 2009; 29(5): 1621 - 1625. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Fasano and F. Muggia Breast cancer arising in a BRCA-mutated background: therapeutic implications from an animal model and drug development Ann. Onc., April 1, 2009; 20(4): 609 - 614. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. L. Chen, W. Xia, and N. L. Spector Acquired Resistance to Small Molecule ErbB2 Tyrosine Kinase Inhibitors Clin. Cancer Res., November 1, 2008; 14(21): 6730 - 6734. [Abstract] [Full Text] [PDF]
|
|